tbuckley/cabot-search huggingface dataset:
Association of Patient-Physician Language Concordance and Glycemic Control for Limited–English Proficiency Latinos With Type 2 Diabetes
Authors: Melissa M. Parker, Alicia Fernández, Howard H. Moffet, Richard W. Grant, Antonia Torreblanca, Andrew J. Karter
Journal: JAMA Internal Medicine (2017)

<h3>Importance</h3> Providing culturally competent care to the growing number of limited–English proficiency (LEP) Latinos with diabetes in the United States is challenging. <h3>Objective</h3> To evaluate changes in risk factor control among LEP Latinos with diabetes who switched from language-discordant (English-only) primary care physicians (PCPs) to language-concordant (Spanish-speaking) PCPs or vice versa. <h3>Design, Setting, and Participants</h3> This pre-post, difference-in-differences study selected 1605 adult patients with diabetes who self-identified as Latino, whose preferred language was Spanish, and who switched PCPs between January 1, 2007, and December 31, 2013. Study participants were members of the Kaiser Permanente Northern California health care system (an integrated health care delivery system with access to bilingual PCPs and/or professional interpreter services). Spanish-speaking and English-only PCPs were identified by self-report or utilization data. <h3>Exposures</h3> Change in patient-PCP language concordance after switching PCPs. <h3>Main Outcomes and Measures</h3> Glycemic control (glycated hemoglobin [HbA<sub>1c</sub>] &lt; 8%), poor glycemic control (HbA<sub>1c</sub> &gt; 9%), low-density-lipoprotein (LDL) control (LDL &lt; 100 mg/dL), and systolic blood pressure (SBP) control (SBP &lt; 140 mm Hg). <h3>Results</h3> Overall, 1605 LEP Latino adults with diabetes (mean [SD] age, 60.5 [13.1] years) were included in this study, and there was a significant net improvement in glycemic and LDL control among patients who switched from language-discordant PCPs to concordant PCPs relative to those who switched from one discordant PCP to another discordant PCP. After adjustment and accounting for secular trends, the prevalence of glycemic control increased by 10% (95% CI, 2% to 17%;<i>P</i> = .01), poor glycemic control decreased by 4% (95% CI, −10% to 2%;<i>P</i> = .16) and LDL control increased by 9% (95% CI, 1% to 17%;<i>P</i> = .03). No significant changes were observed in SBP control. Prevalence of LDL control increased 15% (95% CI, 7% to 24%;<i>P</i> &lt; .001) among LEP Latinos who switched from concordant to discordant PCPs. Risk factor control did not worsen following a PCP switch in any group. <h3>Conclusions and Relevance</h3> We observed significant improvements in glycemic control among LEP Latino patients with diabetes who switched from language-discordant to concordant PCPs. Facilitating language-concordant care may be a strategy for diabetes management among LEP Latinos.
Patient Navigation—An Effective Strategy to Reduce Health Care Costs and Improve Health Outcomes
Authors: Electra D. Paskett, Jessica L. Krok-Schoen, Darrell M. Gray
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Circular RNAs in human cancer
Authors: Yumin Wang, Yongzhen Mo, Zhaojian Gong, Xiang Yang, Mo Yang, Shanshan Zhang, Fang Xiong, Bo Xiang, Ming Zhou, Qianjin Liao, Wenling Zhang, Xiayu Li, Xiaoling Li, Yong Li, Guiyuan Li, Zhaoyang Zeng, Wei Xiong
Journal: Molecular Cancer (2017)

CircRNAs are a novel type of RNAs. With the newly developed technology of next-generation sequencing (NGS), especially RNA-seq technology, over 30,000 circRNAs have already been found. Owing to their unique structure, they are more stable than linear RNAs. CircRNAs play important roles in the carcinogenesis of cancer. The expression of circRNAs is correlated with patients' clinical characteristics, and circRNAs play a vital role in many aspects of malignant phenotypes, including cell cycle, apoptosis, vascularization, and invasion; metastasis as a RNA sponge, binding to RBP; or translation. Therefore, it is meaningful to further study the mechanism of interactions between circRNAs and tumors. The role of circRNAs as molecular markers or potential targets will provide promising application perspectives, such as early tumor diagnosis, therapeutic evaluation, prognosis prediction, and even gene therapy for tumors.
Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials
Authors: F. A. Shepherd, J. Douillard, M. Fukuoka, N. Saijo, S. Kim, T. Cufer, M. V. Sellers, A. A. Armour, E. S. Kim
Journal: Journal of Clinical Oncology (2009)

8011 Background: Four open-label, randomized trials evaluated gefitinib (G) vs docetaxel (D) in unselected patients with pre-treated advanced NSCLC: INTEREST (Lancet 2008; 372: 1809), V-15–32 (J Clin Oncol 2008; 26: 4244), ISTANA (J Clin Oncol 2008; 26: Abs 8025), SIGN (Anticancer Drugs 2006; 17: 401). Reported here is a meta-analysis using the patient data from each of these trials. Methods: The meta-analysis compared efficacy of G (250 mg/day) and D (75 mg/m 2 [V-15–32 60 mg/m 2 ]) using appropriate analysis populations from INTEREST (1466 patients randomized), V-15–32 (489), ISTANA (161) and SIGN (141). Meta-analyses (unadjusted and adjusted for covariates) were performed by Cox proportional hazards for OS and PFS, and by logistic regression for ORR. Results: G demonstrated similar OS and PFS and superior ORR to D in the primary analyses. Secondary analyses demonstrated similar results. Conclusions: Results were consistent with those of the individual studies. Given the similar/superior efficacy demonstrated by G, its favorable tolerability profile, quality of life benefits and oral administration, G has a favorable benefit-risk profile compared with D in a broad pre-treated advanced NSCLC patient population. [Table: see text] [Table: see text]
Indoleamine 2,3-Dioxygenase (IDO) Is Expressed by Multiple Myeloma Plasma Cells and Promotes the Differentiation of Regulatory T Cells: Investigations into the Role of Hepatocyte Growth Factor.
Authors: Giuseppina Bonanno, Maria Corallo, Andrea Mariotti, Anna Di Maggio, Annabella Procoli, Luca De Rosa, Luca Pierelli, Ignazio Majolino, Giuseppe Leone, Raimondo De Cristofaro, Sergio Rutella
Journal: Blood (2008)
The F-BAR Protein PACSIN 2 Specifically Coats the Anastomosing Intracellular Membrane Systems of Platelets and Megakaryocytes,
Authors: Terese Jónsson, Antonija Jurak Begonja, Jan Kormann, Barbara Merkl, Fred Pluthero, Walter H. Kahr, John H. Hartwig, Markus Plomann, Hervé Falet
Journal: Blood (2011)
Incidence and oncologic outcome of renal cell carcinoma in hemodialysis patients detected by annual computed tomography (CT) screening.
Authors: Shingo Hatakeyama, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Noritaka Kamimura, Chikara Ohyama
Journal: Journal of Clinical Oncology (2012)

426 Background: Patients with maintenance hemodialysis (HD) have been recognized as a high risk group for cancer. The aim of this study was to verify the incidence and oncological outcomes of patients on maintenance hemodialysis with renal cell carcinoma (RCC) compared with RCC patients without renal dysfunction. Methods: We have been carried out annual screening for renal mass for the hemodialysis patients.The oncological outcome of pT1N0M0 RCC detected by annual screening of CT imaging were retrospectively reviewed in 1217 patients with HD between January 2002 and December 2010 at Oyokyo kidney Research Institute and Hirosaki University Hospital, Hirosaki, Japan. Overall and cancer specific survival was compared with age matched 106 of pT1N0M0 RCC patients without renal dysfunction who performed radical nephrectomy at the same periods. Results: Among the hemodialysis patients, 14 RCCs were incidentally detected by screening CT examinations and RCC detection rate in HD patients was 0.27% per year. Total 119 pT1N0M0 RCC patients (13 with HD group, 106 normal kidney function group) were incidentally detected by regular abdominal CT imaging without symptoms. There were no significant differences on age and gender between HD and normal kidney function group. Cancer specific survival after tumor diagnosis was not different, but overall survivals were significantly superior in patients without renal dysfunction compared to those with chronic renal failure (P &lt; 0.0001). Cancer specific and Overall 5-year survival was 95% and 96% in patients without renal dysfunction, 92% and 54% in those with chronic renal failure. Conclusions: There was no significant difference in cancer specific survival of pT1 RCC between the two groups. However, overall survival was significantly worse in HD patients. Oncological effectiveness of annual CT screening for the HD patients was not evident in the present retrospective study.
Promising Outcome for Patients with AML-MRC Following Cord Blood Transplantation: Is Induction Chemotherapy Before Transplant Necessary?
Authors: Naoyuki Uchida, Kazuhiro Masuoka, Hikari Ota, Aya Nishida, Kazuya Ishiwata, Masanori Tsuji, Hisashi Yamamoto, Yuki Asano-Mori, Atsushi Wake, Akiko Yoneyama, Shigeyoshi Makino, Koji Izutsu, Shuichi Taniguchi
Journal: Blood (2012)
Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints
Authors: T.R.D.J. Radstake, R. van der Voort, A.W.T. van Lieshout, L.W.J. Toonen, A.W. Sloetjes, W.B. van den Berg, C.G. Figdor, G.J. Adema
Journal: Annals of the Rheumatic Diseases (2005)
Histone Deacetylase Inhibitors Induce Growth Inhibition, Cell Cycle Arrest and Apoptosis in Mantle Cell Lymphoma and Reduce VEGF Production.
Authors: Ulrike Heider, Martin Kaiser, Ivana Zavrski, Jan Sterz, Christian Jakob, Claudia Fleissner, Kurt Possinger, Orhan Sezer
Journal: Blood (2005)
High GRP78 (78-kDa Glucose-Regulated Protein) Expression Predicts for a Favorable Clinical Outcome in Patients with Multiple Myeloma and May be a Potentially Useful Therapeutic Target in the Treatment of Multiple Myeloma
Authors: Hang Quach, Daniel North, Susanna Freddi, Shuh Y Tan, Lenny Straszkowski, Harshal Nandurkar
Journal: Blood (2015)
Efficacy of Mesenchymal Stem Cells for the Treatment of Steroid-Refractory aGVHD
Authors: Kyoko Watakabe, Koichi Miyamura, Yukiyasu Ozawa, Masaya Okada, Takuya Yamashita, Makoto Murata, Takayuki Ishikawa, Naokuni Uike, Michihiro Hidaka, Ryoji Kobayashi, Masahiro Imamura, Junji Tanaka, Kazuteru Ohashi, Shuichi Taniguchi, Takashi Ikeda, Tetsuya Eto, Masaki Mori, Kazuo Muroi, Keiya Ozawa
Journal: Blood (2014)
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis
Authors: Simona Soverini, Caterina De Benedittis, Manuela Mancini, Michela Rondoni, Cristina Papayannidis, Antonella Padella, Giorgina Specchia, Roberta Zanotti, Livio Pagano, Viviana Guadagnuolo, Maria Chiara Fontana, Massimo Delledonne, Alberto Ferrarini, Italo Do Valle, Daniel Remondini, Gastone Castellani, Raffaele Calogero, Serena Merante, Chiara Elena, Peter Valent, Michele Cavo, Giovanni Martinelli
Journal: Blood (2015)
Eribulin for advanced breast cancer: Clinical experience in the real world.
Authors: Richard C. Walshaw, Shazril Shaukat, Kevin Chan, Anne Caroline Armstrong, Sacha Jon Howell, Andrew M. Wardley, Gregory Wilson, Juliet Loncaster, Brian Magee, Lubna Bhatt, Abbas Chittalia, Helen Lander, Christine Tetlow, Vivek Misra
Journal: Journal of Clinical Oncology (2014)

e12003 Background: A number of cytotoxic agents are used for the treatment of advanced breast cancer. Benefit beyond 2 lines of palliative chemotherapy remains poor. Eribulin is a new IV cytotoxic agent that inhibits microtubule dynamics, blocking mitosis irreversibly thus leading to an anticancer effect. The EMBRACE study demonstrated improvement in overall survival (OS) in patients treated with Eribulin when compared to treatment of physician choice, following at least 2 lines of prior treatment. We present response, OS and toxicity data on a cohort of patients treated at our institution with eribulin. Methods: 75 patients treated with eribulin from August 2011 to March 2013 were identified and the electronic patient notes and chemotherapy prescribing system were used to acquire data. Results: 75 patients, median age 53 years (range 40-79) had one or more cycles of eribulin. 23 (31%) had single site metastasis, 48 (64%) had multiple sites. Data unavailable for 4 patients. 70% of patients had ≤3 previous lines of chemotherapy for metastatic disease (range 0-6). 85% had previous capecitabine. Median number of cycles of eribulin was 6; 23 (30.6%) had ≤ 3 cycles, 20 (26.7%) 4 - 6 cycles, 13 (17.3%) 7 - 10 cycles, 19 (25.3%) ≥ 10 cycles. 65 (86.7%) had response assessed radiologically; 56 of who were assessed after cycle 3. At first assessment, 36 (55%) had stable disease, 13 (20%) partial response, 16 (25%) progressive disease. 34 (45%) patients were still alive at time of analysis, with median OS of 11.7 months (range 16 to 742 days) from start of eribulin. The most commonly reported toxicities were lethargy, neuropathy and nausea (55%, 33% and 32% respectively). Neutropenia was reported in 17% of patients, leading to 8 admissions and 1 death due to neutropaenic sepsis. 5 patients had 2 or more admissions during their course of treatment, none more than 3 admissions. We are analysing data further to look at outcomes within subgroups such as receptor status and previous lines of treatment. Conclusions: Our patients achieved a high response rate and OS comparable to the EMBRACE OS of 13.2 months, with an expected and manageable level of toxicity. We have demonstrated effectiveness and safety of this drug in the real world, mirroring findings of the pivotal phase III RCT EMBRACE.
International Good Clinical Practices Guidelines (GCPG) for Antithrombotics in CANCER Patients
Authors: Farge Dominique, Debourdeau Philippe, Beckers Marielle, Caroline Baglin, Rupert Bauersachs, Benjamin Brenner, Dialina Brilhante, Anna Falanga, Grigoris T Gerotziafas, Nissim Haim, Ajay Kakkar, Alok A. Khorana, Ramon Lecumberri, Mario Mandala, Michel Marthy, Manuel Monreal, Shaker S Mousa, Simon Noble, Ingrid Pabinger, Paolo Prandoni, Martin Prins, Mohammed H. Qari, Michael B. Streiff, Konstantin Syrigos, Henri Bounameaux, Harry Roger Buller
Journal: Blood (2012)
Nicotinamide, a Recognized Inhibitor of SIRT1, Promotes Expansion in Ex Vivo Cultures of Short and Long-Term Repopulating Cells.
Authors: Tony Peled, Hadas Shoham, Dorit Aschengrau, Dima Yackoubov, Gabi Frei, Arnon Nagler, Katia Beider, Amnon Peled
Journal: Blood (2009)
Peptides Derived from the CMV Proteome Mimic Unique Stem Cell Transplant Recipient Specific Peptides: Possible Role in Eliciting a Pro-Gvh T Cell Response
Authors: Charles E. Hall, Max Jameson-Lee, Abdelrhman Elnasseh, Vishal Koparde, Allison F. Scalora, Catherine H. Roberts, Nihar U. Sheth, Myrna G. Serrano, Daniel Nixon, Harold M. Chung, Oveimar A. De la Cruz, William B. Clark, John M. McCarty, Gregory A. Buck, Michael C. Neale, Amir A. Toor
Journal: Blood (2015)
IgE and IgE responses to di-isocyanates in spray paint workers : comparison of enzyme immunoassays with various HDIHSA conjugates and immunoCAP
Authors: G. Doekes, A. Pronk, L. Preller, A. Wisnewski, M. Raulf-Heimsoth, J. Lammers, I. Wouters, D. Heederik
Journal: Allergy (2007)
Wound Healing: Delivery of Flightless I Neutralizing Antibody from Porous Silicon Nanoparticles Improves Wound Healing in Diabetic Mice (Adv. Healthcare Mater. 2/2017)
Authors: Christopher T. Turner, Steven J. P. McInnes, Elizabeth Melville, Allison J. Cowin, Nicolas H. Voelcker
Journal: Advanced Healthcare Materials (2017)

The delivery of Flightless neutralizing antibody-loaded porous silicon nanoparticles to diabetic mice wounds significantly improves healing, with porous silicon providing the antibody protection from the protease-rich environment of the wound. This is described by Allison J. Cowin, Nicolas H. Voelcker, and co-workers in article 1600707.
Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma.
Authors: Sally Arai, Renee Letsinger, Laura Johnston, Ginna Laport, Robert Lowsky, David Miklos, Judith Shizuru, Wen-Kai Weng, Ruby Wong, Philip Lavori, Karl Blume, Robert Negrin, Sandra Horning
Journal: Blood (2008)
Genomc-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma.
Authors: Jonathan Keats, Mike Chapman, John Carpten, Wee-Joo Chng, Angela Baker, Gregory Ahmann, Suzanne Trudel, David Siegel, S. Vincent Rajkumar, Melissa Alsina, Paul Richardson, Kenneth Anderson, Daniel Auclair, Louise M. Perkins, Jeffrey Trent, Todd R. Golub, Rafael Fonseca
Journal: Blood (2007)
Fludarabine and Mitoxantrone for the Refractory Relapse Treatment of B-Cell Low-Grade Non-Hodgkin Lymphoma (NHL): LACOHG First Interim Report (Latin American Cooperative Oncology Hematology Group).
Authors: Severiano Baltazar-Arellano, Patricia Pimentel, Luis Vera, Fernando Bezares, Jose Málaga, Julia Huamani-Z, Antonio Montante, Silvia Rivas-Vera, Antonio A. Carrasco-Yalan, Brady E. Beltran-Garate
Journal: Blood (2006)
CD20 B Cell Depleting Therapy Is Associated with up-Regulation of CD8+CD25highFoxp3+ T Regulatory Cells in a Murine Model of Immune Thrombocytopenia (ITP)
Authors: Li Guo, Rukhsana Aslam, Yajing Zhao, Edwin R. Speck, Heyu Ni, John W. Semple
Journal: Blood (2014)
Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone
Authors: Ling Wu, Jingxian Chen, Yiming Wu, Bo Zhang, Xiaochun Cai, Ziwei Zhang, Yan Wang, LongLong Si, Huan Xu, YongXiang Zheng, ChuanLing Zhang, Chenggang Liang, Jing Li, Lihe Zhang, Qiang Zhang, Demin Zhou
Journal: Journal of Controlled Release (2017)
Genetic Disruption of the SH3 and SAM Domains of HACS1 Enhances Adaptive Immunity.
Authors: Dingyan Wang, A. Keith Stewart, Lihua Zhuang, Nancy Xiao, Mawmaw Hlaing, Changxin Shi, Yuanxiao Zhu, Youdong Wang, Xiao-Yan Wen
Journal: Blood (2007)
A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).
Authors: Charles S. Fuchs, Josep Tabernero, Salah-Eddin Al-Batran, Ian Chau, David H. Ilson, Eric Van Cutsem, Kohei Shitara, David Ferry, Michael Emig, Veerle Vanvoorden, Yanzhi Hsu, Yihuan Xu, Andreas Sashegyi, Mayukh Das, Manish A. Shah
Journal: Journal of Clinical Oncology (2016)

TPS178 Background: Ramucirumab, a human IgG1 monoclonal antibody directed to the ectodomain of VEGFR-2, prevents ligand binding to the receptor, blocking activation of downstream receptor-mediated pathways. Ramucirumab has demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) in 2 phase III registration studies (REGARD, RAINBOW) in patients in second-line treatment of gastric cancer. This global phase III trial will compare PFS in patients with HER2-negative, metastatic gastric or GEJ adenocarcinoma receiving ramucirumab with cisplatin/capecitabine (or 5-FU) versus placebo with cisplatin/capecitabine (or 5-FU) as first-line treatment. The trial is conducted in 137 sites in the Americas, Europe and Japan and is currently open to enrollment. Methods: Eligible patients will be randomized to receive ramucirumab (8mg/kg on days 1 and 8, based upon population pharmacokinetic modelling) or placebo with cisplatin/capecitabine every 21-day cycle until disease progression, unacceptable toxicity, or other withdrawal criteria are met. The primary endpoint is PFS; OS is the key secondary endpoint. Efficacy will be considered at 3 analysis points: futility analysis for PFS, primary analysis of PFS &amp; final analysis of OS. A gatekeeping strategy will be used to assess PFS and OS. The OS endpoint will only be tested if the PFS test is significant to control Type I error at 5% across both endpoints. An exposure/safety analysis will be done after 60 patients have started the 3 rd cycle. The study has 90% power to demonstrate a PFS advantage assuming HR = 0.70 and 80% power to demonstrate an OS advantage assuming HR = 0.77. Other secondary endpoints include PFS2 (the time from randomization to disease progression after the start of additional systemic anticancer treatment, or death from any cause, whichever occurs first), objective response rate, safety and quality of life. As of 9/11/2015, 128 patients have been enrolled in 19 countries. The 1 st exposure/safety analysis is underway. Clinical trial information: NCT02314117.
Impact of Erythropoietin Modulation Using Hyperbaric Oxygen on Umbilical Cord Blood CD34+ Cell Homing
Authors: Omar S. Aljitawi, Tara L. Lin, George Vielhauer, Aaron Cheung, Maegan L. Capitano, Dandan Li, Amanda Wise, Brea C. Lipe, Soumen Paul, Mary Laughlin, Hal E. Broxmeyer
Journal: Blood (2015)
Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study
Authors: Jennifer E. Vaughn, Barry E. Storer, Philippe Armand, Roberto Raimondi, Christopher J Gibson, Alessandro Rambaldi, Fabio Ciceri, Rosi Oneto, Benedetto Bruno, Paul J. Martin, Brenda M. Sandmaier, Rainer F. Storb, Mohamed L. Sorror
Journal: Blood (2014)